Food and Drug Administration Warning Letters

Please use this identifier to cite or link to this item: http://10.1.7.192:80/jspui/handle/123456789/9843

Full metadata record

DC Field	Value	Language
dc.contributor.author	Pambhar, Malay N.	-
dc.contributor.author	Patel, Vishvha M.	-
dc.date.accessioned	2021-07-27T09:54:19Z	-
dc.date.available	2021-07-27T09:54:19Z	-
dc.date.issued	2021-05	-
dc.identifier.uri	http://10.1.7.192:80/jspui/handle/123456789/9843	-
dc.description.abstract	FDA warning letters are authorized FDA notice identifying significant regulatory breaches. Letters are usually accomplished in project to make sure that they are read and dealt with as soon as possible. An FDA warning letter, like and FDA 483. If the reason for the FDA warning letter is important enough, the FDA can extend the deadline. It is mandatory to correct the breaches. Here within this report the discussion of transgression in the branches of quality assurance, clinical trials, and stability	en_US
dc.publisher	Institute of Pharmacy, Nirma University, A'bad	en_US
dc.relation.ispartofseries	PPR01058;	-
dc.subject	PPR01058	en_US
dc.subject	B. Pharm Project Report	en_US
dc.subject	Pharmaceutical Analysis	en_US
dc.subject	Food and Drug Administration (FDA)	en_US
dc.subject	Regulatory Violations	en_US
dc.subject	17BPH049	en_US
dc.subject	17BPH106	en_US
dc.subject	FDA warning letter	en_US
dc.subject	Quality Assurance	en_US
dc.subject	Clinical Trials	en_US
dc.title	Food and Drug Administration Warning Letters	en_US
dc.type	Project Report	en_US
Appears in Collections:	B. Pharm Project Reports

Files in This Item:

File	Description	Size	Format
PPR01058.pdf	PPR01058	2.61 MB	Adobe PDF	View/Open

IR @ Nirma University